Recently Featured
Laboratory technician analyzing biologics samples

Glycosylation Control Becomes Priority in Biologics Development

November 7, 2026
Drug manufacturers must now prioritize glycosylation control in the development of complex biologics, including bispecific antibodies, antibody-drug conjugates, and Fc-fusion proteins. These newer therapeutics are sensitive to glycan heterogeneity, which can directly affect their efficacy and consistency. Historically, manufacturers addressed glycosylation issues during downstream processing. However, modern biologics require proactive upstream quality engineering to mitigate…
Scientist working in a cancer research lab

NYU Study Identifies DNA Replication Issues Affecting PARP Inhibitor Response

November 6, 2026
A study led by researchers at NYU Langone Health’s Perlmutter Cancer Center identifies specific DNA replication issues that affect how cancer cells respond to PARP inhibitors. The research, published in Nature Cell Biology, highlights the role of the ESCO2 protein in determining sensitivity to these drugs. The team found that even a partial loss of…
Advertising campaign for pharmaceutical industry

Pharmaceutical Group Spent $59 Million on Search Ads

November 6, 2026
The lobbying group for the U.S. pharmaceutical industry spent an estimated $59 million on search advertising over a recent seven-year period to influence public opinion on prescription drug costs. The Pharmaceutical Research & Manufacturers of America (PhRMA) accounted for roughly $32 million of this spending on ads related to insurance and health plan searches, while…
Scientist working in a cancer research lab

Boehringer Ingelheim Inks Up-to-$7.4B Cancer Drug Collaboration with Sino Biopharmaceutical

November 6, 2026
Boehringer Ingelheim has launched an up-to-$7.358 billion-plus collaboration with Sino Biopharmaceutical (SBP Group) to develop next-generation cancer therapies based on antibody-drug conjugate (ADC) and T-cell engager (TcE) technologies. The companies signed a strategic multi-program option and license agreement to deepen their existing partnership in oncology, which includes three Boehringer-developed cancer treatments initiated in 2024. The…

Ongoing Cases